FLNA ▼ -1.4% - Filana Therapeutics, Inc. $FLNA Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Filana Therapeutics' stock fell 1.4% despite the company's announcement that the FDA has lifted a clinical hold on its drug simufilam, clearing the way for a Phase 2a study in patients with tuberous sclerosis complex-related epilepsy. The seemingly positive regulatory development may have disappointed investors expecting a larger market opportunity or more advanced clinical progress than a Phase 2a designation suggests. 22-SEP-2026 08:01 AM ET